India Strengthens Regulation of GLP-1 Weight Loss Drug Supply Chain India’s drug regulatory authority has intensified its oversight of the distribution and use of GLP-1-based weight loss medications, launching a nationwide enforcement campaign to address illegal activities and ensure compliance with safety standards. The Central Drugs Standard Control Organisation (CDSCO), working alongside state Licensing Authorities (SLAs), has conducted comprehensive inspections and audits across multiple regions to target non-compliant practices, including improper dispensing and misuse of these drugs. The initiative aims to reinforce adherence to the conditions of approval and label warnings for GLP-1-based weight loss treatments. State drug controllers have been directed to enhance monitoring of the entire supply chain, from manufacturing to retail, to prevent unauthorized distribution. Authorities are also urged to collaborate with the Advertising Standards Council of India (ASCI) and other relevant bodies to ensure strict enforcement of regulations. Over the past several weeks, the campaign has focused on identifying and addressing violations in the distribution chain, which has raised concerns about the potential risks associated with these medications. The enforcement efforts include coordinated inspections of pharmacies, healthcare providers, and other entities involved in the supply of GLP-1 drugs. The regulator emphasized the need for strict compliance to protect public health and prevent the proliferation of counterfeit or substandard products. The move comes amid growing scrutiny of GLP-1 drugs, which have gained popularity for their effectiveness in weight management but also face challenges related to accessibility and misuse.#advertising_standards_council_of_india #pharmaceutical_sector #glp_1_drugs #central_drugs_standard_control_organisation #state_licensing_authorities
